TICKERNERD
Menu
VRCAVRCAHealthcare · Biotechnology

VRCA Stock Forecast: Verrica Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$4.82
−0.82% on the day

The 6 Wall Street analysts covering Verrica Pharmaceuticals, Inc. hold a median 12-month price target of $13 — +169.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 21 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$83.1M
Ticker Nerd rank
72 / 100
Median analyst target
$13
Analysts covering
6
Total return, dividends reinvested
1W
−3.0%
1M
−11.4%
YTD
−42.0%
1Y
−16.0%
From 52W high
−47.0%
From 52W low
+47.0%
$3.28
$9.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VRCA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Verrica Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
72 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Quality
79
Growth
79
Size
77
Issuance
64
Value
61
Momentum
38
Revisions
27
Volatility
23

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (23): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VRCA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VRCA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26VRCAHigh $20Median $13Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
5 Buy1 Hold0 Sell
Low $10Median $13High $20

The green dot is the last close — the median target sits +169.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 May 2026HC Wainwright & Co.AssumesBuy$12
18 Dec 2025Brookline CapitalUpgradeBuy—
14 May 2025NeedhamReiteratesHold—
9 Apr 2025NeedhamReiteratesHold—
8 Apr 2025HC Wainwright & Co.ReiteratesNeutral—
12 Mar 2025NeedhamReiteratesHold—
20 Dec 2024NeedhamReiteratesHold—
6 Nov 2024HC Wainwright & Co.DowngradeNeutral—
5 Nov 2024NeedhamReiteratesHold—
5 Nov 2024RBC CapitalDowngradeSector Perform—
21 Oct 2024TD CowenMaintainsBuy—
4 Oct 2024RBC CapitalMaintainsOutperform—
3 Oct 2024NeedhamDowngradeHold—
2 Oct 2024Brookline CapitalDowngradeHold—
15 Aug 2024NeedhamMaintainsBuy—
15 Aug 2024RBC CapitalMaintainsOutperform—
16 May 2024NeedhamReiteratesBuy—
14 May 2024HC Wainwright & Co.MaintainsBuy—
14 May 2024NeedhamMaintainsBuy—
10 Apr 2024NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VRCA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

VRCA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Verrica Pharmaceuticals, Inc. (VRCA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.9×

Cheaper than 87% of US stocks

Price / sales
2.7×

Cheaper than 45% of US stocks

Price / book
18.9×

Cheaper than 6% of US stocks

EV / EBITDA
−2.9×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
−53.9%

Higher than 5% of US stocks

Earnings growth (YoY)
−53.8%

Higher than 9% of US stocks

Gross margin
85.0%

Higher than 94% of US stocks

Operating margin
−194.5%

Higher than 11% of US stocks

Net margin
−102.8%

Higher than 6% of US stocks

Returns & dividend
Return on equity
−72.3%

Higher than 17% of US stocks

Return on assets
−44.0%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VRCA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VRCAVerrica Pharmaceuticals, Inc.$83.1M
72
MAIAMAIA Biotechnology, Inc.$84.3M
20
DWTXDogwood Therapeutics, Inc.$84.6M
37
ELOXEloxx Pharmaceuticals, Inc.$84.7M
15
GANXGain Therapeutics, Inc.$84.7M
29
CINGCingulate, Inc.$80.7M
28
ELTXElicio Therapeutics, Inc.$79.9M
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Verrica Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VRCA news & analysis

Verrica Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Verrica Pharmaceuticals reported second-quarter revenue growth for its YCANTH treatment, progress in pivotal studies for common warts, and a new credit facility that management says could extend its cash runway into 2028.

Why it matters — The update touches on all three key drivers for VRCA — revenue growth of its marketed product, pipeline advancement, and improved financial runway — making it a comprehensive check-in for shareholders.

Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for Verrica Pharmaceuticals Inc. (VRCA). The transcript covers the company's quarterly earnings discussion presented on the call.

Why it matters — A VRCA watcher would care because the earnings call transcript provides management's own account of the company's quarterly results and outlook.

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 7 Aug 2026neutral

Verrica Pharmaceuticals reported a Q2 loss of $0.48 per share, narrower than the Zacks Consensus Estimate of a $0.56 loss. This compares with earnings of $0.02 per share in the same period a year earlier, while revenue beat estimates.

Why it matters — A VRCA watcher would note that, despite the year-over-year decline from a profit to a loss, the company's results came in better than analysts expected with a revenue beat.

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

GlobeNewsWire · 30 July 2026neutral

Verrica Pharmaceuticals announced it will release its second quarter 2026 financial results and provide a corporate update on August 6, 2026, followed by a conference call and live webcast at 4:30 p.m.

Why it matters — The financial results and corporate update will provide investors with the latest performance data and strategic outlook for the company.

FAQ

Frequently asked questions about VRCA stock

What is the VRCA stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Verrica Pharmaceuticals, Inc. have a median 12-month price target of $13, with estimates ranging from $10 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VRCA stock a buy right now?

Of the 6 analysts covering Verrica Pharmaceuticals, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Verrica Pharmaceuticals, Inc. 72 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VRCA?

As at 21 Aug 2026, Verrica Pharmaceuticals, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

Will VRCA stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +169.7% from the last close, and Ticker Nerd's factor model ranks Verrica Pharmaceuticals, Inc. 72 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VRCA stock forecast for 2030?

No analyst covering Verrica Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRCA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $20 over the next 12 months.

How has VRCA stock performed over the past year?

Verrica Pharmaceuticals, Inc. returned -16.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Verrica Pharmaceuticals, Inc. do?

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and commercializing medications for the treatment of skin diseases in the United States.

What is the latest news on VRCA?

The most recent item we track (MarketBeat, 7 Aug 2026): "Verrica Pharmaceuticals Q2 Earnings Call Highlights". Verrica Pharmaceuticals reported second-quarter revenue growth for its YCANTH treatment, progress in pivotal studies for common warts, and a new credit facility that management says could extend its cash runway into 2028.

Company

About Verrica Pharmaceuticals, Inc.

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and commercializing medications for the treatment of skin diseases in the United States. The company's primary product is YCANTH (VP-102), a drug-device combination featuring a topical cantharidin solution with a precision applicator designed for treating molluscum contagiosum and common warts in both adult and pediatric patients. The product has received regulatory approval in Japan and is advancing through phase III clinical trials for additional indications. Verrica also develops VP-315, an oncolytic peptide-based injectable therapy currently in phase II trials for dermatologic oncology conditions, including basal cell carcinoma. The company generates revenue through direct product sales and collaboration agreements with international partners. Headquartered in West Chester, Pennsylvania, Verrica operates with a focused pipeline addressing significant unmet needs in viral and oncologic skin diseases, positioning itself as an innovative player in the specialized dermatology therapeutics market.

CEO Dr. Jayson M. Rieger M.B.A., Ph.D. · 76 employees · United States · https://www.verrica.com